Latest Low-density lipoprotein Stories
- Alirocumab, an investigational treatment for hypercholesterolemia, showed a 62 percent reduction in LDL-C compared to placebo at 24 weeks on top of maximally-tolerated lipid-lowering therapy in ODYSSEY
Study Meets Co-Primary Endpoints of LDL Cholesterol Reduction THOUSAND OAKS, Calif., Aug.
Represents First BLA Submission for a PCSK9 Inhibitor THOUSAND OAKS, Calif., Aug.
The cholesterol-lowering drug fenofibrate cuts cardiovascular disease risks by 30 percent in women with type-2 diabetes, a new University of Sydney study reveals.
A Mayo Clinic task force challenges some recommendations in the updated guideline for cholesterol treatment unveiled by the American College of Cardiology (ACC) and American Heart Association (AHA) in 2013.
A Rise In Lipitor Lawsuit Claims Jumped In Five Months With Filings That Contend Development Of Type 2 Diabetes After Taking The Cholesterol Lowing Medication, Notes Wright & Schulte LLC
Primary efficacy endpoints met in all nine new trials of investigational PCSK9 inhibitor TARRYTOWN, N.Y. and PARIS, July 30, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc.
- Primary efficacy endpoints met in all nine new trials of investigational PCSK9 inhibitor - PARIS and TARRYTOWN, N.Y., July 30, 2014 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and
Diet Doc’s new cholesterol diet plans focus on helping people in any part of the country lose weight fast and improve their health by reducing bad cholesterol levels Dallas,
- Emitting flashes of light; glittering.